GlassScriptPhysician profile
David P Batt
NPI 1518212265
$955.38
in general payments reported to CMS, 2019-2025
16 companies · $94.84 in 2025
The $94.84 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $180 · 2023: $209 · 2024: $283 · 2025: $94.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $429.39 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $90.07 | 2023-2024 | |
| Ucb, INC. | $89.86 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $52.85 | 2021-2024 | |
| Biofrontera INC. | $44.14 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $36.38 | 2021-2023 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $36.18 | 2021 | |
| Amgen INC. | $32.43 | 2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $31.48 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $22.81 | 2024 | Dupixent |
| Leo Pharma INC. | $19.46 | 2022 | |
| Incyte Corporation | $18.92 | 2024 | Opzelura |
| Dermavant Sciences, INC. | $13.87 | 2024 | Vtama |
| Genzyme Corporation | $13.25 | 2021 | |
| Dermira, INC. | $12.68 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $11.61 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Batt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.